Amytrx Therapeutics, a US-based biopharmaceutical company specialising in the development of novel therapies for dermatology and inflammation, announced on Tuesday that it has added Dr Michael Howell and Dr Satish Joshi as its new directors.
Dr Howell has over 20 years of experience in allergy, autoimmunity, dermatology, inflammatory and oncology diseases. He has played an important role in various clinical trials and has published extensively on topics regarding dermatological and immunological conditions.
Dr Joshi has more than 25 years of experience in the peptide API business. He has been at the forefront of peptide product development throughout his career.
Dr Matthew A. Gonda, Amytrx Therapeutics CEO, said: "Amytrx Therapeutics is excited to welcome Dr. Howell and Dr. Joshi to our board of directors. Their exceptional scientific and business backgrounds align perfectly with our mission to bring transformative treatments to patients in need. Their contributions will be invaluable as we continue to advance our lead candidate, AMTX-100, and work towards its successful commercialisation."
Ionis Pharmaceuticals names new executive vice president, chief global product strategy officer
Allergy Therapeutics reports positive G306 Phase III trial results for Grass MATA MPL
NeoImmuneTech's NT-I7 receives US FDA Orphan Drug Designation
Allergy Therapeutics reports positive interim results for G306 Phase III trial
Inimmune signs research collaboration with Boston Children's Hospital
ResVita Bio receives USD250,000 phase one Small Business Innovation Research grant from NIAID
Phase II Data of Oral Dexpramipexole Published in Eosinophilic Asthma
AllerVie Health Rebrands Southern Allergy & Asthma
Applied BioCode Inks Distribution Agreement with Medline Industries
Vedanta Biosciences Receives Fast Track Designation for VE303
KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop
French Ophthalmology Specialist Horus Pharma Group Launches a Nordic Subsidiary